- $11.45bn
- $16.05bn
- $4.38bn
Catalent quarterly sales inch past estimates amid Novo Holdings' takeover (updated)
Catalent reports second-quarter revenue slightly above estimates
Brief: Catalent Q2 Revenue USD 1,030 Million Vs. IBES Estimate USD 1,013 Million
Newscasts - US Markets Briefing: S&P 500 hovers near 5,000; earnings, jobs data in focus
What to Watch in the Day Ahead - Friday, February 9
Astrazeneca says Catalent deal shows need for in-house capacity (updated)
Astrazeneca says Catalent deal shows importance of in-house capacity
US FDA finds control lapses at Catalent plant being sold to Novo (updated)
EU watchdog is looking into availability of drugs made at Catalent sites sold to Novo (updated)
EU watchdog to assess availability of drugs made at Catalent sites sold to Novo
Catalent Inc expected to post a loss of 2 cents a share - Earnings Preview
US FDA finds control lapses at Catalent plant being sold to Novo
Media: Wegovy maker Catalent's Indiana plant isn't meeting safety & quality standards- Bloomberg News
Brief: Lilly Expects Concord Site To Begin Production Of GlP-1 Drugs As Early As 2024-End
Novo digs $11.5 bln moat around weight-loss jewel
U.S. RESEARCH ROUNDUP-Air Products and Chemicals , Hubspot and McDonald's
Press Digest: British Business - Feb 6
Newscasts - U.S. Markets Briefing: Wall Streets falls ahead of another busy corporate day for markets
U.S. STOCKS ON THE MOVE-MorphoSys AG, DocuSign, Invitae